Reduce Patient Risk of Transfusion-Associated Sepsis

Cerus Final Intercept United States 3

According to the FDA, platelet components are uniquely vulnerable to bacterial outgrowth because of their room temperature storage and are associated with a higher risk of sepsis and related fatality than other transfusible components1.

 Was it the platelets

  • Conventional platelets are susceptible to bacterial contamination
  • Room temperature storage facilitates bacterial growth
    • Sensitivity of primary culture is only 26-44%1-3
    • Utility of secondary testing is constrained by its limit of detection4
  • Sepsis and bacterial infections attributed to platelets are underrepresented due to passive reporting5
  • Hospital-acquired infections are associated with platelet transfusions6
  • Colonized central lines can be caused by contaminated platelets7

Significantly reduce your patient’s risk of transfusion-associated sepsis with The INTERCEPT® Blood System for Platelets

 

 

 


  1. FDA. Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use. Docket No. FDA-2006-N-0040. Fed Regist 2015;80:29842-906.